Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts ...

And although Pfizer's deal is with a China-based company, Pfizer said it plans to manufacture drug substance for SSGJ-7807 in Sanford, N.C., and make drug product in McPherson, Kan. As Evercore ...

Pfizer will pay $1.25 billion upfront to license an experimental cancer drug out of China ... Citigroup raised 3SBio’s price target to HK$21.00 ($2.7) from HK$13.00 after the deal.

Pfizer Inc. plans to spend billions of dollars to join the race for a new type of cancer treatment. Similar to its competitors, Pfizer also plans to partner with a Chinese company. The company PFE ...

Pharmaceutical giant Pfizer Inc. PFE has signed a significant licensing agreement with China's 3SBio Inc. for an experimental cancer drug, SSGJ-707. According to the deal, Pfizer will pay $1.25 ...

The agreement covers the development, manufacturing and commercialisation of the drug. Pfizer has been granted a global license, excluding China, as well as the option to obtain commercialisation ...

US pharma major Pfizer (NYSE: PFE) is stepping up its presence in the high-stakes field of bispecific immuno-oncology with a licensing deal worth up to $6 billion for a Chinese-developed drug that ...

(Reuters) -U.S. drugmaker Pfizer said on Monday it has signed a licensing agreement worth about $6 billion with Chinese biopharmaceutical company 3SBio Inc for the development, manufacturing and ...

Additional milestone payments could reach up to $4.8 billion, alongside tiered double-digit royalties on future sales if the drug receives approval ... planning details or potential impacts on ...